These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 26397936)

  • 41. Efficacy and safety of subcutaneous and intravenous rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in first-line diffuse large B-cell lymphoma: the randomized MabEase study.
    Lugtenburg P; Avivi I; Berenschot H; Ilhan O; Marolleau JP; Nagler A; Rueda A; Tani M; Turgut M; Osborne S; Smith R; Pfreundschuh M
    Haematologica; 2017 Nov; 102(11):1913-1922. PubMed ID: 28935843
    [TBL] [Abstract][Full Text] [Related]  

  • 42. R2-CHOP vs R-CHOP for diffuse large B-cell lymphoma.
    Fowler NH
    Clin Adv Hematol Oncol; 2014 Sep; 12(9):608-10. PubMed ID: 25654483
    [No Abstract]   [Full Text] [Related]  

  • 43. Male gender is an independent predictor for worse survival and relapse in a large, consecutive cohort of elderly DLBCL patients treated with R-CHOP.
    Eyre TA; Martinez-Calle N; Hildyard C; Eyre DW; Plaschkes H; Griffith J; Wolf J; Fields PA; Gunawan A; Oliver R; Booth S; McMillan A; Fox CP; Bishton M; Collins GP; Hatton CSR
    Br J Haematol; 2019 Aug; 186(4):e94-e98. PubMed ID: 31020646
    [No Abstract]   [Full Text] [Related]  

  • 44. Quality of life research: adding an important dimension to the evaluation of therapeutic outcomes.
    Hamilton AS
    Leuk Lymphoma; 2011 Mar; 52(3):353-4. PubMed ID: 21323516
    [No Abstract]   [Full Text] [Related]  

  • 45. Phase 3 study of frontline rituximab, cyclophosphamide, doxorubicin, and prednisone plus vincristine (R-CHOP) or bortezomib (VR-CAP) in transplantation-unsuitable mantle cell lymphoma (MCL) patients.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):9-11. PubMed ID: 25768994
    [No Abstract]   [Full Text] [Related]  

  • 46. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
    Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
    Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Prognostic impact of p53 aberrations for R-CHOP-treated patients with diffuse large B-cell lymphoma.
    Stefancikova L; Moulis M; Fabian P; Vasova I; Zedek F; Ravcukova B; Muzik J; Kuglik P; Vranova V; Falkova I; Hrabalkova R; Smardova J
    Int J Oncol; 2011 Dec; 39(6):1413-20. PubMed ID: 21874232
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Lenalidomide plus R-CHOP21 in newly diagnosed diffuse large B-cell lymphoma (DLBCL): long-term follow-up results from a combined analysis from two phase 2 trials.
    Castellino A; Chiappella A; LaPlant BR; Pederson LD; Gaidano G; Macon WR; Inghirami G; Reeder CB; Tucci A; King RL; Congiu A; Foran JM; Pavone V; Rivera CE; Spina M; Ansell SM; Cavallo F; Molinari AL; Ciccone G; Habermann TM; Witzig TE; Vitolo U; Nowakowski GS
    Blood Cancer J; 2018 Nov; 8(11):108. PubMed ID: 30410035
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased rituximab (R) doses eliminate increased risk and improve outcome of elderly male patients with aggressive CD20+ B-cell lymphomas: the SEXIE-R-CHOP-14 trial of the DSHNHL.
    Clin Adv Hematol Oncol; 2014 Aug; 12(8 Suppl 16):8-9. PubMed ID: 25768993
    [No Abstract]   [Full Text] [Related]  

  • 50. High-risk diffuse large B-cell lymphoma: can we do better than rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone?
    George A; Tam CS; Seymour JF
    Leuk Lymphoma; 2013 Dec; 54(12):2575-6. PubMed ID: 23597141
    [No Abstract]   [Full Text] [Related]  

  • 51. Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B.
    Molina TJ; Canioni D; Copie-Bergman C; Recher C; Brière J; Haioun C; Berger F; Fermé C; Copin MC; Casasnovas O; Thieblemont C; Petrella T; Leroy K; Salles G; Fabiani B; Morschauser F; Mounier N; Coiffier B; Jardin F; Gaulard P; Jais JP; Tilly H
    J Clin Oncol; 2014 Dec; 32(35):3996-4003. PubMed ID: 25385729
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Single nucleotide polymorphisms in ABCB1 and CBR1 can predict toxicity to R-CHOP type regimens in patients with diffuse non-Hodgkin lymphoma.
    Jordheim LP; Ribrag V; Ghesquieres H; Pallardy S; Delarue R; Tilly H; Haioun C; Jardin F; Demangel D; Salles GA; Dumontet C
    Haematologica; 2015 May; 100(5):e204-6. PubMed ID: 25637052
    [No Abstract]   [Full Text] [Related]  

  • 53. A comparison of pectoralis versus lumbar skeletal muscle indices for defining sarcopenia in diffuse large B-cell lymphoma - two are better than one.
    Go SI; Park MJ; Song HN; Kim HG; Kang MH; Kang JH; Kim HR; Lee GW
    Oncotarget; 2017 Jul; 8(29):47007-47019. PubMed ID: 28388585
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma.
    Musolino A; Boggiani D; Panebianco M; Vasini G; Salvagni S; Franciosi V; Ardizzoni A
    Cancer; 2011 Mar; 117(5):964-73. PubMed ID: 20960528
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
    Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
    Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Autologous stem cell transplantation remains beneficial for patients relapsing after R-CHOP chemotherapy and who respond to salvage chemotherapy.
    Moore S; Peggs K; Thomson K; Lowry L; Ljubic A; Goldstone AH; Linch DC; Ardeshna KM
    Br J Haematol; 2012 Jan; 156(1):142-3. PubMed ID: 21848889
    [No Abstract]   [Full Text] [Related]  

  • 57. Long-term follow-up of patients with HIV-related diffuse large B-cell lymphomas treated in a phase II study with rituximab and CHOP.
    Ribera JM; Morgades M; González-Barca E; Miralles P; López-Guillermo A; Gardella S; López A; Abella E; García M; Navarro JT; Feliu E
    Br J Haematol; 2012 Jun; 157(5):637-9. PubMed ID: 22313456
    [No Abstract]   [Full Text] [Related]  

  • 58. Interim PET Scans in Diffuse Large B-Cell Lymphoma: Is It Ready for Prime Time?
    Bolshinsky M; Nabhan C
    Clin Lymphoma Myeloma Leuk; 2016 Dec; 16(12):655-661. PubMed ID: 27693134
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cyclophosphamide, doxorubicin, vincristine, prednisone and rituximab versus epirubicin, cyclophosphamide, vinblastine, prednisone and rituximab for the initial treatment of elderly "fit" patients with diffuse large B-cell lymphoma: results from the ANZINTER3 trial of the Intergruppo Italiano Linfomi.
    Merli F; Luminari S; Rossi G; Mammi C; Marcheselli L; Tucci A; Ilariucci F; Chiappella A; Musso M; Di Rocco A; Stelitano C; Alvarez I; Baldini L; Mazza P; Salvi F; Arcari A; Fragasso A; Gobbi PG; Liberati AM; Federico M
    Leuk Lymphoma; 2012 Apr; 53(4):581-8. PubMed ID: 21895543
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Peripheral blood absolute lymphocyte/monocyte ratio during rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone treatment cycles predicts clinical outcomes in diffuse large B-cell lymphoma.
    Porrata LF; Ristow KM; Habermann TM; Witzig TE; Colgan JP; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Nowakowski G; Thompson CA; Markovic SN
    Leuk Lymphoma; 2014 Dec; 55(12):2728-38. PubMed ID: 24547705
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.